


**Product Name** : Ifidancitinib  
**Cat. No.** : PC-49397  
**CAS No.** : 1236667-40-5  
**Molecular Formula** : C<sub>20</sub>H<sub>18</sub>FN<sub>5</sub>O<sub>3</sub>  
**Molecular Weight** : 395.394  
**Target** : JAK  
**Solubility** : 10 mM in DMSO



## Biological Activity

Ifidancitinib (ATI-502, ATI-50002, R507) is a potent and selective next-generation JAK1/3 inhibitor, potently inhibits  $\gamma$ c cytokine signaling.

Ifidancitinib strongly inhibited IL-2-stimulated STAT5 phosphorylation in mouse T cells.

Ifidancitinib also exhibited potent inhibitory effects on JAK1/2-mediated IFN- $\gamma$  signaling.

Ifidancitinib treatment significantly reduced the population of NKG2D+CD8+ T cells in a dose-dependent manner.

Ifidancitinib impaired murine T cell proliferation and human T cell function in vitro and in vivo.

Ifidancitinib prevented the onset of alopecia in alopecia areata (AA) skin grafted C3H/HeJ mice.

Ifidancitinib induced multiple co-inhibitory receptors in CD44+CD62L- CD8+ T cells.

Ifidancitinib exhibited potent anti-inflammatory effects both in vitro and in C3H/HeJ mice in vivo, suppressed IFN- $\gamma$  signaling with the reduced expression of IFN- $\gamma$ -dependent genes such as MHC class I, CXCL10, and CXCL11.

## References

Zhenpeng Dai, et al. Front Immunol. 2022 Sep 20;13:955038.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com